Two Sigma Investments LP Has $405,000 Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Two Sigma Investments LP grew its stake in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 123.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 137,334 shares of the company’s stock after acquiring an additional 75,792 shares during the period. Two Sigma Investments LP owned 0.49% of Vistagen Therapeutics worth $405,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Blair William & Co. IL lifted its position in shares of Vistagen Therapeutics by 11.3% in the fourth quarter. Blair William & Co. IL now owns 98,466 shares of the company’s stock worth $290,000 after buying an additional 10,000 shares during the last quarter. Millennium Management LLC raised its stake in shares of Vistagen Therapeutics by 52.9% in the 4th quarter. Millennium Management LLC now owns 38,732 shares of the company’s stock valued at $114,000 after acquiring an additional 13,395 shares in the last quarter. Man Group plc acquired a new stake in Vistagen Therapeutics in the 4th quarter worth approximately $54,000. Bank of America Corp DE grew its holdings in Vistagen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after purchasing an additional 19,331 shares during the last quarter. Finally, Boothbay Fund Management LLC acquired a new position in Vistagen Therapeutics during the fourth quarter valued at approximately $66,000. 78.39% of the stock is owned by institutional investors and hedge funds.

Vistagen Therapeutics Trading Down 0.8%

Shares of Vistagen Therapeutics stock opened at $2.34 on Tuesday. Vistagen Therapeutics, Inc. has a 1 year low of $1.90 and a 1 year high of $4.21. The company’s fifty day simple moving average is $2.29 and its 200-day simple moving average is $2.59. The company has a market cap of $67.54 million, a price-to-earnings ratio of -1.58 and a beta of 0.70.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.